Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
Open label, randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer. The study aim is to compare disease-free survival between treatment arms: BCG alone versus Mitomycin in addition to BCG.
Epistemonikos ID: e5f6abc5028dec2622002abc46eec85b4662afab
First added on: May 17, 2024